$Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag$

Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag

Severe refractory ITP is clinically challenging and a variety of single or combination chemotherapies have been tried with limited outcome. We report a case of ITP that was unresponsive to multiple agents including high-dose steroid, IVIG, Rho(D) immune globulin, rituximab, cyclosporine, azathioprin...

Full description

Bibliographic Details
Main Authors:	Faiz Anwer, Seongseok Yun, Anju Nair, Yusuf Ahmad, Ravitharan Krishnadashan, H. Joachim Deeg
Format:	Article
Language:	English
Published:	Hindawi Limited 2015-01-01
Series:	Case Reports in Hematology
Online Access:	http://dx.doi.org/10.1155/2015/583451

Similar Items

Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag
by: Anwer, Faiz, et al.
Published: (2015)

Cerebral venous thrombosis in refractory idiopathic thrombocytopenia treated with eltrombopag
by: Vivek Nambiar, et al.
Published: (2016-01-01)

Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia
by: Alhossain A. Khalafallah, et al.
Published: (2012-01-01)

Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease
by: Juan Wang, et al.
Published: (2021-03-01)

Eltrombopag use for refractory immune thrombocytopenia in pregnancy: A case report
by: Sarah J. Weingarten, et al.
Published: (2021-01-01)

Eltrombopag Improves Refractory Thrombocytopenia in a Patient with Systemic Lupus Erythematosus
by: Natsuki Shima, et al.
Published: (2018-01-01)

The Use of High Dose Eltrombopag in the Management of Sepsis-Associated Thrombocytopenia in Critically Ill Patients
by: Hasan Md. Jahidul, et al.
Published: (2019-11-01)

Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
by: Lambert MP
Published: (2016-06-01)

A case of immune thrombocytopenia due to miliary tuberculosis effectively treated with eltrombopag
by: Hiroshi Wada, et al.
Published: (2020-01-01)

Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia
by: Alessandra Di Paola, et al.
Published: (2021-12-01)

Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag
by: Danish Fazal, et al.
Published: (2010-01-01)

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
by: Danish FA, et al.
Published: (2013-03-01)

Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag
by: Rajakrishnan Vijayakrishnan, et al.
Published: (2011-03-01)

Successful Long-Term Use of Eltrombopag in a Patient with Refractory Severe Thrombocytopenia Associated with Chronic Lymphocytic Leukemia That Allowed Oral Anticoagulant Treatment for Severe Cardiomyopathy
by: Juárez Salcedo Luis Miguel, et al.
Published: (2017-01-01)

Eltrombopag for thrombocytopenia following pediatric allogeneic hematopoietic stem cell transplantation
by: A. Akyay, et al.
Published: (2020-10-01)

Eltrombopag-Induced Myelofibrosis in Patients with Adult Immune Thrombocytopenia: Scoping Review
by: Iman Moustafa, et al.
Published: (2019-08-01)

Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
by: Elbedewy TA, et al.
Published: (2019-02-01)

Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis
by: Hafiz Abdul Waqas Ahmed MD, et al.
Published: (2021-04-01)

Role of thrombopoietin stimulating agents(Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE
by: Toro Vélez, Esteban, et al.
Published: (2021-07-01)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia
by: Arnold, D.M, et al.
Published: (2022)

Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors
by: María Henar García Lagunar, et al.
Published: (2015-02-01)

Eltrombopag Can Achieve Treatment Free Remission as Upfront Therapy for Patient with Immune Thrombocytopenia
by: Khaldun Obeidat, et al.
Published: (2021-04-01)

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain
by: Eduardo Anguita, et al.
Published: (2020-11-01)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
by: Tremblay G, et al.
Published: (2018-11-01)

Recurrent Coronary Thrombus in a Patient with Chronic Immune Thrombocytopenia with Treatment Using Eltrombopag
by: Terumori Satoh, et al.
Published: (2019-01-01)

Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
by: Allen, J., et al.
Published: (2021)

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach
by: Maria L. Lozano, et al.
Published: (2021-06-01)

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
by: Tremblay G, et al.
Published: (2018-11-01)

The pharmacology of eltrombopag-dose selection in preclinical and clinical studies
by: Jenkins, Julian
Published: (2011)

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation
by: Semra Aydin, et al.
Published: (2020-10-01)

Intermittent versus Daily Eltrombopag Dosage Protocols for the Treatment of Primary Immune Thrombocytopenia: Real-Life Experience
by: Elbedewy TA, et al.
Published: (2020-12-01)

Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still’s Disease
by: Yoshika Tsuji, et al.
Published: (2015-01-01)

Eltrombopag Use for Treatment of Thrombocytopenia in a Patient with Chronic Liver Disease and Portal Vein Thrombosis: Case Report
by: Sabah E. Mohamed, et al.
Published: (2020-07-01)

Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report
by: Gabriella Gruden, et al.
Published: (2021-04-01)

Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide
by: Tania Caroline Monteiro de Castro, et al.

Eltrombopag in Good’s Syndrome
by: Håvard Anton Kristiansen, et al.
Published: (2014-01-01)

A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia
by: Qiuhua Zhu, et al.
Published: (2021-08-01)

First Report of Severe Autoimmune Hemolytic Anemia During Eltrombopag Therapy in Waldenström Macroglobulinemia-Associated Thrombocytopenia
by: Shen Y, et al.
Published: (2021-10-01)

Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
by: Jiaxing Zhang, et al.
Published: (2018-01-01)

An infant with refractory cytomegalovirus‐induced thrombocytopenia
by: Suguru Uemura, et al.
Published: (2020-01-01)

Cannot write session to /tmp/vufind_sessions/sess_d4bd4orqulmpc9n1l634sqivlj